Drugmakers may need designated expert to certify batches before sale

India’s Union health ministry proposes requiring every drugmaker to appoint a qualified and experienced person to authorise each medicine batch before sale. This would create a clearly identified decision-maker for a crucial quality-control step. The change is part of draft amendments to the Drugs Rules, 1945.

Companies would need to review a batch’s quality information and paperwork before distribution. They would then issue a Batch Release Certificate in a prescribed format and retain batch-release records for every lot produced. The designated person would be responsible for authorising that release.

Currently, manufacturers must identify technical staff overseeing production and testing, but no specific provision names the person approving a batch for sale. The ministry says the proposal would strengthen good manufacturing practice compliance, improve oversight, and make release decisions traceable. The public has 30 days to submit objections and suggestions.

Batch release is the formal decision to allow a specific lot of medicine to enter distribution. It happens after the manufacturer reviews the batch’s relevant quality parameters and documentation. The purpose is to confirm that the lot is ready to be supplied.

The process is broader than checking a single test result. It involves an overall review of the information connected with the batch, including quality findings and required records. Under the proposal, a suitably qualified and experienced person would authorise this decision and take clear responsibility for it.

The ministry calls batch release a critical stage in pharmaceutical manufacturing. Naming the decision-maker would improve accountability and traceability. It would also support compliance with good manufacturing practices. If a problem later emerges, the records could show who authorised the batch and what information supported that decision.

The drug manufacturer would be responsible for designating the batch-release decision-maker. The proposed rules describe this person as suitably qualified and experienced. Their job would be to authorise the release of each batch for distribution.

This person would review the batch’s relevant quality parameters and documentation before approving it. The manufacturer would also need to maintain records of the release decision. These requirements would connect the approval to an identifiable individual rather than leaving responsibility with the company generally.

The article does not state a specific educational qualification, job title, or number of years of experience. It says only that the person must be suitably qualified and experienced. The ministry expects this explicit responsibility to strengthen accountability, improve oversight of product quality, and make decisions traceable if concerns arise later.

Before a batch can be released for distribution, drugmakers would need to document the decision formally. The proposed amendments require a Batch Release Certificate in a prescribed format. Companies would also have to maintain batch-release records for every lot produced.

These documents would capture the approval process around each batch. A designated, suitably qualified and experienced person would review the relevant quality parameters and documentation, then authorise release. The records would preserve evidence of that decision and the information considered.

The ministry says the requirements would ensure traceability of batch-release decisions and add oversight of product quality. They would also support manufacturers’ compliance with applicable good manufacturing practices. The article does not list every field that the certificate must contain. It says the format and requirements would be prescribed under the revised regulatory structure.

Assigning a specific batch-release expert would clarify who authorised a medicine lot for sale. That matters because the current rules identify personnel overseeing manufacturing and testing but do not specifically identify the person approving release. Clear responsibility can strengthen accountability.

The expert would review quality parameters and documentation before signing off. The company would issue a Batch Release Certificate and retain records for every lot. Together, the named decision-maker and supporting paperwork would create a traceable record of what was approved and when.

The ministry says this structure would provide additional oversight of product quality and reinforce compliance with good manufacturing practices. If a quality problem is later found, investigators could follow the batch-release records and examine the decision process. The proposal does not guarantee that mistakes will disappear, but it is designed to make responsibility and regulatory review clearer.

Good manufacturing practices, or GMP, are documented procedures and controls used to ensure medicines are consistently made and tested to required quality standards. They cover activities such as production, testing, recordkeeping, equipment, and staff responsibilities. GMP helps prevent contamination, mix-ups, and unreliable results.

For example, a manufacturer should control how a batch is produced, test relevant quality parameters, and review the supporting documents before release. The proposed Indian rules would add a named person for that final decision, along with a certificate and records. This gives the GMP system a clearer release checkpoint.

GMP is essential because medicines must be dependable from batch to batch. A final review cannot replace controlled manufacturing, but it can identify problems before distribution. The health ministry says the proposed amendments would help manufacturers strengthen compliance with applicable GMP and reinforce the regulatory framework for drug quality. The article does not provide a full GMP definition.